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INTRODUCTION
Sepsis is characterized by an uncontrolled inﬂammatory as well
as anti-inﬂammatory process driven by the host immune sys-
tem in response to bacteria (Adib-Conquy and Cavaillon, 2012).
This syndrome is one of the leading causes of death in intensive
care units worldwide and its incidence is progressively increas-
ing (Kotsaki and Giamarellos-Bourboulis, 2012). Although major
wall components of Gram-positive bacteria (peptidoglycan and
lipoteichoc acid) can induce sepsis, the highest incidence of this
syndrome is caused by lipopolysaccharides (LPSs) from Gram-
negative bacteria (De Kimpe et al., 1995). Consequently, research
in this ﬁeld has been focused on LPS. LPSs are the major molecu-
lar component of the outer membrane of Gram-negative bacteria.
This molecule represents a pathogen-associated molecular pattern
(PAMP), responsible for the development of local inﬂammatory
response through Toll-like receptor-4 (TLR-4) signaling (Miller
et al., 2005). The inﬂammatory response is essential for bacte-
rial clearence, but in extreme cases an exacerbated reaction may
lead to septic shock (Salomao et al., 2012). Unfortunately, despite
substantial advances in the pathophysiology of sepsis, there is no
efﬁcacious therapy against this syndrome yet (Schulte et al., 2013).
As a consequence, septic shock syndrome continues to increase,
reaching mortality rates over 50% in some cases (Buttenschoen
et al., 2010).
In this context, the search for new therapeutics that can
inhibit the activation of the innate immune system by LPS is
of major importance (Pulido et al., 2012). Even though many
studies in animal models and clinical trials have been con-
ducted, there is no effective drug yet that interacts directly
against LPS (Buttenschoen et al., 2010). Host-defense peptides
(HDPs) could be a possible alternative solution since they pos-
sess antimicrobial, antiseptic, and immunomodulatory properties
(Giuliani et al., 2010). These molecules have been identiﬁed as
a defense strategy across many forms of life from prokaryotic
organisms to vertebrates (Zasloff, 2002). HDPs are generally
small, commonly having around 12–50 amino acid residues,
cationic (net charge of +2 to +7), and are frequently quite
hydrophobic and amphipathic (Jenssen et al., 2006). Further-
more, binding to diverse chemotypes of LPS and inhibition
of LPS-induced pro-inﬂammatory cytokines from macrophages
have been demonstrated for different HDPs (Scott et al., 2000;
Lee et al., 2010). Interestingly, none of them have been iso-
lated taking advantage of their afﬁnity to LPS. As the search for
new LPS-binding peptides is imperative for the development of
more effective therapies, the use of LPS immobilized on dif-
ferent supports could be useful and suitable for isolating them.
This approach could expand the rational search for anti-LPS
HDPs.
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LIPOPOLYSACCHARIDE ENDOTOXIN
Lipopolysaccharides are the major molecular component of the
outer membrane of Gram-negative bacteria. This molecule is
essential for the survival of Gram-negative bacteria, contributing
to the correct assembly of the outer membrane. In this context,
LPS provides a permeability barrier to many different classes of
molecules such as detergents, antibiotics, and metals. Due to their
localization, LPS molecules participate in host-bacterium interac-
tions like adhesion, colonization, virulence, and symbiosis (Silipo
and Molinaro, 2011).
Lipopolysaccharide is an amphiphilic molecule composed of
three domains: lipid A, core oligosaccharide, and O-antigen
repeats. Lipid A represents the hydrophobic component of LPS,
which is located in the outer leaﬂet of the outer membrane
and carries the endotoxic properties of LPS. This domain is the
most conserved region of the lipopolysaccharide molecule. The
hydrophilic portion of the molecule is composed of the glycan, O-
antigen. The core oligosaccharide joins the lipid A and O-antigen
domains. The core oligosaccharide domain can be divided into
two regions: the inner core (proximal to lipid A) and the outer
core (proximal to O-antigen). In contrast to lipid A, core oligosac-
charide and O-antigen domains are displayed on the surface of
bacteria (Brandenburg et al., 2010).
The activation of the immune system by LPS occurs through
the transmembrane protein TLR-4, a pattern recognition receptor
(PRR) found on the surface of many cells from the innate immune
system. MD-2, a small membrane-bound glycoprotein, associates
with TLR-4 for the recognition of LPS. Other proteins such as
CD14 and LPS-binding protein (LBP) enable the interaction of
LPS with MD-2. After LPS recognition, TLR4 homodimerises,
initiating the recruitment of intracellular adapter molecules such
as MyD88, Mal, Trif, and Tram and leading to the expression of
diverse inﬂammatory genes (Miller et al., 2005; Bryant et al., 2010;
Mcgettrick and O’Neill, 2010).
ANTI-LIPOPOLYSACCHARIDE HOST-DEFENSE PEPTIDES
The efﬁcacy of HDPs against Gram-negative bacteria has been
widely documented (Vaara, 2009; Cao et al., 2010; Park et al.,
2011). The antimicrobial activity of these molecules is not only
a consequence of their direct action against bacteria (at the cel-
lular membrane and/or intracellular targets) but also of their
anti-infective (modulation of the immune system) capacity (Hale
and Hancock, 2007; Wieczorek et al., 2010). Although the outer
membrane of Gram-negative bacteria constitutes an excellent per-
meability barrier to antibacterial agents, the interaction of HDPs
with LPS permits this resistance mechanism to be bypassed. The
process by HDPs across the outer membrane has been termed
self-promoted uptake (Sawyer et al., 1988). In this mechanism,
the peptides ﬁrstly interact with the negative surface of LPS and
competitively displace the divalent cations that bridge the LPS bar-
rier. This causes disturbance of the outer membrane, promoting
peptide movement through it.
Host-defense peptides are very attractive molecules for use
as therapeutics against septic syndrome due to their afﬁnity
for LPS and their antibacterial activity (Pulido et al., 2012). In
fact, a number of natural HDPs from various sources bind
to diverse chemotypes of LPS and reduce LPS-induced release
of pro-inﬂammatory cytokines (Bowdish and Hancock, 2005;
Bhattacharjya, 2010). For example, in vitro and in vivo LPS neu-
tralization by the human cathelicidin peptide LL-37 has been
demonstrated (Scott et al., 2002). The pretreatment of monocytes
with this peptide inhibited Pseudomonas aeruginosa LPS-induced
IL-8 production.
Interestingly, pro-inﬂammatory cytokine inhibition was abol-
ished upon removal of LL-37 from the media before LPS stim-
ulation, suggesting that the capacity of LL-37 to inhibit LPS
signalling is dependent on extracellular LPS neutralization (Scott
et al., 2011). Nevertheless, LL-37 may also have direct effects on
macrophage function. Scott et al. (2002) demonstrated the upreg-
ulation of 29 genes and downregulation of another 20 genes in
macrophages treated with the peptide using gene expression pro-
ﬁling experiments. Among the genes predicted to be up-regulated
by LL-37 were those encoding chemokines and chemokine recep-
tors, without stimulating the pro-inﬂammatory cytokine, TNF-α.
Furthermore, an intracellular receptor for this peptide in mono-
cytes has been discovered (Mookherjee et al., 2009). In order to
increase the antiendotoxic activity of LL-37, various cathelicidin-
derivedpeptides have been studied (Nagaoka et al., 2002;Nell et al.,
2005). The antiendotoxic activity can be improved by increas-
ing the hydrophobicity and cationicity of the parental peptide
(Nagaoka et al., 2002). The LPS neutralization capacity of catheli-
cidins from another species has also been proved (Tossi et al., 1994;
Tack et al., 2002; Bhunia et al., 2009).
Although the LPS neutralization properties of α-defensins are
low (Scott et al., 2000), a potent antiendotoxic activity for some β-
defensins has been established (Motzkus et al., 2006). Indeed, it has
recently been demonstrated that LPS-binding activity and TNF-α
release inhibition in RAW264.7 cultures for the human β-defensin
DEFB114. Additionally, protection against LPS-induced reduc-
tion of human sperm motility in vitro and LPS-induced lethality
of D-galactosamine-sensitized C57BL/6 mice were also demon-
strated for DEFB114 (Yu et al., 2013). The antiendotoxic activity
of DEFB114 was dependent on disulﬁde bond. On the other hand,
ﬂuorescence experiments demonstrated that DEFB126, another
human β-defensin with anti-sepsis activity, can penetrate RAW
264.7 cells and diminish the production of LPS-stimulated inﬂam-
matory factors. In the sameway,DEFB126might alsoparticipate in
intracellular immune regulation beyond its direct LPS neutraliza-
tion (Liu et al., 2013). PerhapsDEFB126 uses a similar intracellular
pathway to that of LL-37. Moreover, the differences in the
antiendotoxic activity between α-defensins and β-defensins sug-
gested that antibacterial activities do not necessarily correlate with
anti-LPS properties (Bhattacharjya, 2010). Finally, the anti-LPS
properties of invertebrate defensins have also been demonstrated
(Saido-Sakanaka et al., 2004; Koyama et al., 2006). Other HDPs
also have the capacity to inhibit LPS effects (Jacks et al., 1996; Gia-
cometti et al., 2006; Lin et al., 2013; Schadich et al., 2013). These
examples evidence the natural role of HDPs in the defense against
LPS-induced septic shock.
Different mechanisms of LPS inhibition have been described
for HDPs (Pulido et al., 2012). In general, the direct interaction
of HDPs can disaggregate, or induce a change in the unil-
amellar/cubic structure of LPS to multilamellar, inhibiting the
recognition of this molecule by the immune receptor complex
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(Andra et al., 2005; Kaconis et al., 2011; Singh et al., 2013). Besides,
HDPs also can inhibit LPS-induced sepsis by their modulation of
immune cells. In this context, the inhibition of pro-inﬂammatory
mediators (Liu et al., 2013), inhibition of surface expression of
TLR-4 by interacting with microtubules (Li et al., 2013), and the
normalization of the coagulation (Kalle et al., 2012) have been
demonstrated.
Otherwise, the structural knowledge of LPS-high afﬁnity
binders such as Limulus anti-LPS factor (Hoess et al., 1993),
Bactericidal/permeability-increasing protein (Beamer et al., 1997),
Factor C (Tan et al., 2000) and Polymyxin B (Pristovsek and
Kidric, 1999) among others has allowed the development of
synthetic antiendotoxic peptides (Pristovsek and Kidric, 2001;
Andra et al., 2006; Ding et al., 2008). Although preclinical data
are very encouraging, only one of the synthetic variants, the
recombinant fragment of protein BPI (rBPI21), has been tested
successfully in clinical studies (Domingues et al., 2012). The
situation is similar for natural compounds where there is no
Food and Drug Administration (FDA)-approved drug yet that
interacts directly against LPS. Only the apheresis procedures
for endotoxin adsorption with Polymyxin B (lipopeptide pro-
duced by the bacterium Bacillus polymyxa) immobilized in the
ﬁber column have been used for the treatment of septic shock
patients in Japan since 1994 (Ruberto et al., 2013). Due to
the failure to obtain antiendotoxic molecules with clinical efﬁ-
cacy, searching for new LPS-binding peptides is imperative
(Giuliani et al., 2010).
LIPOPOLYSACCHARIDE IMMOBILIZATION
Afﬁnity chromatography is one of the most efﬁcient protein
puriﬁcation strategies. This technique is a method for selective
puriﬁcation of molecules from complex mixtures based on highly
speciﬁc biological interaction between the immobilized ligand and
the molecule of interest. The highly selective interactions that
guide this procedure allow for a fast, often single-step process,
with potential for puriﬁcation in the order of several hundred
to 1000-fold (Urh et al., 2009). Successful afﬁnity puriﬁcation is
determined by the selection of a suitable support and immobilized
ligand. The afﬁnity support (the matrix onto which the ligand is
immobilized) should selectively capture the molecule of interest
while at the same time exhibiting low non-speciﬁc adsorption
(Gustavsson and Larsson, 2006).
ISOLATION OF LIPOPOLYSACCHARIDE-BINDING PROTEINS
Afﬁnity supports based on LPS immobilization could be a power-
ful tool for the isolation of anti-LPS HDPs. Indeed, the isolation
of LBPs using these supports has been described (Minetti et al.,
1991; Chiou et al., 2000; Shahriar et al., 2006). For instance, the
Limulus endotoxin-binding protein-protease inhibitor (LEBP-PI),
a 12 kDa protein from Limulus amebocytes, was puriﬁed using
an LPS afﬁnity column. In this study, the authors immobilized
LPSs onto Afﬁ-Gel Hz support (Bio-Rad). This support is based
on hydrazide coupling chemistry. Afﬁ-Gel Hz hydrazide gel is an
agarose supportwhich reacts with the aldehydes of oxidized carbo-
hydrates (periodate oxidation) to form stable, covalent hydrazone
bonds (O’Shannessy and Wilchek, 1990). A high yield of active
LEBP-PI was achieved after elution with LPS or sodium citrate
(Minetti et al., 1991). On the other hand, Chiou et al. (2000)
isolated an LBP by afﬁnity chromatography based on LPS from
Escherichia coli O55:B5 coupled to cyanogen bromide (CNBr)
activated Sepharose CL-4B. The isolated glycoprotein showed an
apparent molecular mass of about 40 kDa and 72.2% identity to
tachylectin-3, a lectin isolated from the amebocyte of T. triden-
tatus, previously characterized by its afﬁnity to the O-antigen of
LPS. Shahriar et al. (2006) also used LPS-afﬁnity chromatogra-
phy for isolation of LBPs in porcine milk. The afﬁnity support
was prepared by coupling 100 mg of E. coli F4 LPS – 3 g of
CNBr-activated Sepharose 4B. Low afﬁnity LBPs were eluted using
mild conditions (Tris 10 mM, 1 M NaCl, pH 7.2) whereas high
afﬁnity binders were eluted using 0.1 M glycine-HCl, pH 2.5.
The LBPs lactoferrin, soluble CD14, serum amyloid A, alpha-
S1 casein, beta-casein, and kappa-casein were isolated by this
approach. The coupling reagent used in the last two examples
for synthesizing the afﬁnity support was CNBr, which is very
efﬁcient for immobilizing proteins. It activates hydroxyl groups
on the resin to create reactive cyanate esters, which then can be
coupled to amine-containing ligands forming an isourea bond
(Urh et al., 2009). The LPS molecule is thus immobilized on these
resins by their hexosamines located at the core outer region and in
lipid A.
ISOLATION OF LIPOPOLYSACCHARIDE-NEUTRALIZING PEPTIDES
Despite the success in purifying LBPs by afﬁnity chromatography,
this approach has not yet been used for isolating anti-LPS HDPs.
The idea that interaction of LPS and anti-LPS peptides could be
affected when one of them is immobilized on a matrix is possi-
ble, and therefore isolating anti-LPS peptides with immobilized
LPS could be less efﬁcient. Nevertheless, an interesting attempt
to study LPS interaction with anti-LPS peptides when the latter
were immobilized (Gustafsson et al., 2010) showed that immobi-
lization of HDPs does not inhibit their capacity to neutralize LPS,
although there are differences between the peptides assayed. The
interaction of LPS with immobilized peptides was efﬁcient both in
LPS binding and inhibiting cytokine production induced by LPS.
Otherwise, the binding of HDPs to LPS occurs through the lipid
A moiety: speciﬁcally, basic aminoacids interact with phosphates
and hydrophobic aminoacids with the acyl chains (Bhattachar-
jya et al., 2007). For this reason, the immobilization of LPS using
hexosamines located in the lipid A region may affect recognition
by HDPs. Therefore, a conjugation method keeping free the lipid
A moiety in the lipopolysaccharide molecule could be more efﬁ-
cient to immobilize LPS for the isolation of anti-LPS HDPs. In
fact, Pallarola and Battaglini (2008, 2009) performed the coupling
of LPS with probes bearing hydrazine or primary amino groups.
LPS was modiﬁed through the activation of the hydroxyl groups
present in its O-antigen moiety. Conjugates with good labeling
ratios were obtained with the preservation of its endotoxic activ-
ity. A similar strategy was discussed above for the puriﬁcation of
LEBP-PI (Minetti et al., 1991). Otherwise, LPSmolecules are capa-
ble of formmicelles and aggregates even at very low concentrations
(Yu et al., 2006). For this reason, the efﬁciency of LPS immobi-
lization could be extremely low. Unfortunately, there is no data
reported about the efﬁciency of LPS immobilization. Moreover,
the coupling of LPS through the O-antigen domain may render a
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FIGURE 1 | Scheme of LPS immobilization on affinity supports. (1)
Activated supports. (2) Coupling reagents. (3) Miscellar lipid A immobilized
on afﬁnity supports. (4) Zoom of the interaction of lipid A with the activated
supports. (A) Cyanogen bromide activated support. (B) Glyoxyl activated
support. (C) Ethyloxy-6-aminocaproic acid activated support.
higher immobilization efﬁciency than coupling LPS through hex-
osamines due to the poor reactivity of the latter (Eller et al., 2000).
Nevertheless, the LPS immobilization through hexosamines could
not be discarded due the large numbers of commercial resins that
could be activated to react with amine groups (Urh et al., 2009).
In this sense, the accurate use of coupling reagents may inﬂu-
ences on the LPS afﬁnity support synthesis. For example, coupling
reagents with a higher length seems to better interact with LPS
(Figure 1).
On the other hand, magnetic ﬁeld-based separations using
magnetic nanoparticles have received considerable attention in
the last two decades (Horak et al., 2007). This methodology can be
used on viscous materials, simplifying the puriﬁcation process by
removing sample pretreatment. Furthermore, the highly speciﬁc
surface area of the nanoparticles enables the immobilization of a
larger amount of molecule. Therefore, the immobilization of LPS
on magnetic nanoparticles could be a very attractive procedure
for isolating anti-LPSHDPs bymagnetic separation. Although this
approach has not been used yet, there are different examples of LPS
immobilization on magnetic nanoparticles (Fornara et al., 2008;
Piazza et al., 2011). For example, LPS was reversibly immobilized
in a magnetic nanoparticle system consisting of oleylamine-
coated iron oxide nanocrystals by hydrophobic interactions.
LPS-magnetic nanoparticles were stable enough to mimic natu-
ral LPS aggregates for investigating the interaction of the LPS with
TLR4 receptor (Piazza et al., 2011). In another approach, Fornara
et al. (2008) synthesized magnetic nanoparticles for detection
of Brucella antibodies in biological samples. Thermally blocked
nanoparticles obtained by thermal hydrolysis were functionalized
with LPS from Brucella abortus. LPS was attached to magnetic
nanoparticles by adsorption through hydrophobic interactions,
and the variation in magnetic relaxation due to surface bind-
ing of antibodies to LPS-functionalized nanoparticles was used
to detect the disease. This method showed high sensitivity, with
detection limit of 0.05 μg/mL of antibody in the biological sam-
ples without any pretreatment. Interestingly, the same approach
could be used for detecting anti-LBPs from different sources.
The same principle is not feasible for HDPs due to their small
molecular weight. Furthermore, both systems described above
could be used as afﬁnity puriﬁcation procedures, but the stability
of hydrophobic LPS-functionalized nanoparticles in drastic elu-
tion conditions (0.1 M glycine-HCl, pH 2.5) would have to be
evaluated.
Aswas exempliﬁed above, the synthesis of afﬁnity supports is no
longer used only for puriﬁcation of speciﬁc biomolecules. It is also
rapidly becoming a method of choice to study biological interac-
tions. In fact, Genfa et al. (2005) identiﬁed LPS-binding molecules
in herb fractions by coating afﬁnity optical biosensor cuvettes
with lipid A via hydrophobic interactions after pre-incubating
extracts with LPS. Such a concept demonstrated that LPS can
be immobilized, keeping its ability to efﬁciently bind LPS bind-
ing molecules, and it could represent a high-throughput approach
for the identiﬁcation of LPS-neutralizing peptides (Zheng et al.,
2010).
CONCLUDING REMARKS
Despite substantial advances in the pathophysiology of sepsis,
there is no effective therapy against this syndrome yet. A thera-
peutic alternative could be the use of HDPs due to the capacity
of some of them to neutralize LPS. As it is vital to ﬁnd new LPS-
binding peptides for the development of more effective therapies,
the use of LPS immobilized on different supports could be useful
and suitable for isolating them. This approach could expand the
rational search for anti-LPS HDPs.
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